Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday backed approval of Moderna's flu vaccine for adults aged 50 and older, saying its ...

Two drug companies had a bad week. AstraZeneca (AZN) lost 12.06% last week, while Moderna (MRNA) fell by 14.41%. AZN stock ...

The FDA advisory panel unanimously supported mRNA-1010/mFLUSIVA for adults 50–64 and 65+, and the stock is already reacting ...

A first-of-its-kind flu shot is one step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for ...

Arbutus (ABUS) looks stronger after Moderna validates its LNP patents, with imdusiran showing durable viral control and a ...

Moderna's mRNA flu vaccine could be approved by August, but federal policy and a nonfunctional advisory committee threaten ...

A new kind of flu vaccine is moving a step closer to the U.S. market.

Today, in STAT’s Brooklyn outpost we’re drinking — yes, heresies of heresies — plain old water. Sometimes you have to give ...

A Food and Drug Administration advisory panel on Thursday recommended the approval of Moderna’s mRNA-based flu shot for older adults.